Analyst INSIGHTS: Teva Pharmaceutical and 4 Stocks with New Analysis

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): Deutsche Bank added Teva to a short-term buy list.

Crown Castle International Corp. (NYSE:CCI): Following its meeting with Crown Castle management, Stifel believes that Crown Castle will still find attractive secular growth trends pushing demand for shared wireless infrastructure beneficial. The firm reiterates its Buy rating and $62 price target on the stock.

Don’t Miss: A.M. Buzzers: Barnes & Noble to Team Up with Microsoft? Groupon Jumps 8%.

Nxstage Medical, Inc. (NASDAQ:NXTM): On Friday, Aetna (NYSE:AET) released a policy update which states that home hemodialysis via NxStage Medical’s (NASDAQ:NXTM) System One machine is “medically necessary” instead of its prior label of “experimental.” Leerink sees this a possibly NxStage’s step closer to being established as routine care and sees the current levels of shares as attractive.

Hologic Inc. (NASDAQ:HOLX): According to Jefferies, its analysis indicates that significant earnings for the combined company can be drivent by Hologic’s acquisition of Gen-Probe (NASDAQ:GPRO). The firm thinks that when combined, by FY15, the companies could generate $2.68 in EPS, which includes nearly $1.00 in the Gen-Probe deal’s incremental earnings. Because Jefferies sees Hologic shares as attractive at current levels, the firm maintains a Buy rating with a $24 price target on shares.

Celgene Corporation (NASDAQ:CELG): This week, Barclays believes that there is a favorable risk/reward in store for The Committee for Medicinal Products for Human Use of the European Medicines Agency’s anticipated decision regarding Revlimid. According to the firm, shares could increase up to the mid-$70’s with a label recommendation in patients post stem cell transplant, and with no recommendation, it could see a $5-$6 decrease. The firm also states that a floor for shares will be provided by the $2.5B share repurchase and the anticipated apremilast data. The firm gives an Overweight rating and an $83 price target on shares.

Don’t Miss: Will Microsoft’s New Tablet CHALLENGE Apple or Amazon?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business